01 / IDENTITY
Compound Profile
SEQUENCE
Ala-Glu-Asp-Gly (AEDG)
ORIGIN
Developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology (Russia). Part of the peptide bioregulator series — short peptides isolated from specific tissues that act as epigenetic regulators for those same tissues. Cartalax is derived from cartilage tissue.
MECHANISM — EPIGENETIC GENE REGULATION
Khavinson peptides work via chromatin interaction. The tetrapeptide AEDG binds directly to DNA and histone complexes in the cell nucleus, acting as an epigenetic switch that turns on genes responsible for chondrocyte (cartilage cell) proliferation, collagen synthesis, and extracellular matrix production. This is fundamentally different from receptor-based peptide mechanisms.
TARGET TISSUE
Primary: articular cartilage, intervertebral disc tissue, synovial joint membranes. Secondary: connective tissue throughout the musculoskeletal system. Cartalax preferentially accumulates in cartilaginous tissue after administration.
KHAVINSON PEPTIDE SERIES CONTEXT
Cartalax belongs to the same research lineage as Epitalon (AEDG pineal), Cortagen (nervous system), Vilon (immune), and Livagen (liver). Each is a 4-amino-acid tissue-specific bioregulator. The series represents 40+ years of Russian gerontology research with human longevity data.
ORAL BIOAVAILABILITY
Unlike most peptides, Cartalax tetrapeptide is small enough (4 AA) to survive partial GI transit and be absorbed sublingually or enterically. Both SC injection and oral/sublingual administration show clinical activity, though SC is more reliable for systemic dosing.
02 / RESEARCH HISTORY
Development Timeline
1970s–1980s
Professor Khavinson and colleagues at the Soviet Institute of Bioregulation begin systematically isolating short peptides from different organ tissues. The hypothesis: each tissue contains its own bioregulatory peptides that can restore the tissue's gene expression to a younger, more functional state.
1990s
Cartalax (AEDG) identified as the bioregulatory peptide specific to cartilaginous tissue. Animal studies demonstrate chondrocyte proliferation, increased proteoglycan synthesis, and reduced cartilage degradation in aging and arthritic models.
2000s
Human trials in Russia: patients with osteoarthritis treated with Cartalax show reduced pain scores, improved joint mobility, and cartilage preservation on imaging. Studies conducted in elderly populations with degenerative joint disease.
2010s–Present
Epigenetic mechanism studies confirm AEDG peptide directly interacts with chromatin. X-ray crystallography and molecular modeling show AEDG binds to histone-DNA complexes at specific gene promoter regions — confirming direct gene regulatory activity rather than receptor-mediated signaling. Published in peer-reviewed gerontology journals.
03 / BENEFITS & MECHANISMS
Research-Supported Effects
01
Chondrocyte Proliferation — Cartilage Cell Regeneration
Cartalax activates gene expression in chondrocytes (the cells that make and maintain cartilage). In aging cartilage, chondrocyte activity declines and cell density falls. AEDG reverses gene silencing in these cells, restoring their synthetic activity. Animal studies show measurable increase in chondrocyte density and proteoglycan content after Cartalax treatment.
02
Proteoglycan & Collagen II Synthesis
Articular cartilage is primarily composed of type II collagen and proteoglycans (aggrecan, versican). These provide the compressive strength and viscoelasticity that protects joints. Cartalax upregulates genes encoding collagen II and aggrecan production — restoring the molecular composition of aging cartilage toward a younger profile.
03
MMP Inhibition — Stops Cartilage Breakdown
Matrix metalloproteinases (MMP-13, MMP-3) are enzymes that degrade cartilage matrix in osteoarthritis. Cartalax reduces MMP expression while simultaneously increasing TIMP (tissue inhibitor of metalloproteinases) — creating a net anti-catabolic environment. Less breakdown + more synthesis = net cartilage preservation.
04
Intervertebral Disc Support
The nucleus pulposus (core of intervertebral discs) contains disc cells (notochordal cells, fibrocartilage) with similar biology to articular chondrocytes. Cartalax's gene regulatory activity extends to these cells — relevant for disc degeneration, herniation recovery, and lumbar/cervical health. Particularly valuable stacked with BPC-157 for comprehensive spine support.
05
Epigenetic Anti-Aging — Gene Expression Reset
The AEDG mechanism is fundamentally epigenetic — it doesn't just stimulate chondrocytes temporarily, it resets the gene expression profile of aging cartilage tissue toward a younger state. In the context of the full Khavinson bioregulator system, Cartalax is part of a tissue-specific epigenetic rejuvenation approach that has produced measurable longevity outcomes in Russian cohort studies.
Joint Stack: Cartalax (cartilage gene activation) + AOD-9604 (chondroprotection via TGF-β) + BPC-157 (local angiogenesis and repair) + TB-500 (systemic anti-inflammatory) = comprehensive four-mechanism joint regeneration protocol covering gene expression, growth factor signaling, blood supply, and inflammation.
04 / RECONSTITUTION
Vial Preparation
STANDARD VIAL — 20mg
20mg vial + 3.0 mL (300 units) bacteriostatic water
Concentration: 66.7 mcg per unit (0.01 mL)
| DOSE | MCG | UNITS ON SYRINGE | VOLUME |
|---|
| LOW |
1,000mcg (1mg) |
15 units |
0.15 mL |
| STANDARD |
2,000mcg (2mg) |
30 units |
0.30 mL |
| HIGH |
5,000mcg (5mg) |
75 units |
0.75 mL |
Oral/Sublingual Alternative: Cartalax can also be used sublingually (dissolved under tongue) or orally as a capsule from some compounding pharmacies. SC injection provides more reliable systemic bioavailability. Oral/sublingual preferred for GI/mucosal delivery or when injection is not preferred.
Storage: Lyophilized stable at room temp 6 months. Refrigerate post-reconstitution (2–8°C), use within 28 days. Protect from light.
05 / DOSING PROTOCOL
Dose Ranges
| PROTOCOL | DOSE | FREQUENCY | USE CASE |
|---|
| MAINTENANCE |
1mgdaily |
Daily SC or oral |
Preventive joint health, longevity, mild OA prevention |
| STANDARD |
2mgdaily |
Daily SC |
Active OA, cartilage preservation, joint injury recovery |
| INTENSIVE |
5mgdaily |
Daily SC × 10–20 days |
Pulsed high-dose course for significant cartilage restoration — Khavinson protocol approach |
Pulsed Protocol (Khavinson Method): Like Epitalon, Cartalax may be most effective as a pulsed intensive course rather than continuous low-dose. 5mg/day × 10 days, then off 1–3 months, then repeat. This mimics the episodic gene activation pattern seen in the original Russian clinical studies.
06 / TIMING & ADMINISTRATION
Injection Protocol
TIMING
No fasting requirement. Morning injection preferred for consistency. Evening acceptable.
INJECTION SITE
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites. For knee/hip OA: some practitioners inject closer to the affected joint SC area — though systemic SC achieves cartilage tissue distribution regardless of site.
COMPREHENSIVE JOINT PROTOCOL
Cartalax 2mg AM + AOD-9604 500mcg AM (TGF-β chondroprotection) + BPC-157 500mcg (local angiogenesis). For systemic support add TB-500 2mg 2×/week. This four-compound approach covers all known mechanisms of cartilage regeneration.
SYNERGY WITH EPITALON
Cartalax + Epitalon is a powerful longevity combination from the Khavinson series. Epitalon targets pineal/telomere/systemic aging; Cartalax targets cartilage/connective tissue aging. Together: tissue-specific + systemic anti-aging gene regulation. Run concurrently or in back-to-back pulsed cycles.
07 / BIOMARKER MONITORING
Recommended Lab Panel
CARTILAGE & JOINT MARKERS
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| COMPcartilage oligomeric matrix protein |
CLINICAL<10 µg/mL |
OPTIMAL<5 µg/mL |
Elevated in active cartilage breakdown. Reduction indicates chondroprotective activity. |
| CTX-IIC-terminal telopeptide of collagen II (urine) |
CLINICALVaries by age/sex |
OPTIMALDecreasing vs. baseline |
Specific marker of type II collagen (cartilage) breakdown. Should decrease with effective Cartalax treatment. |
| MMP-3matrix metalloproteinase-3 — serum |
CLINICALVaries |
OPTIMALDecreasing vs. baseline |
Cartilage-degrading enzyme. Cartalax should reduce MMP-3 via gene regulatory inhibition. |
| Joint MRIradiographic |
CLINICAL— |
OPTIMALPreserved or improved |
Pre/post 12-week MRI for cartilage volume and joint space width. Gold standard assessment. |
INFLAMMATION
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| hs-CRPhigh-sensitivity C-reactive protein |
CLINICAL<3.0 mg/L |
OPTIMAL<0.5 mg/L |
Systemic inflammation drives OA progression. Track alongside cartilage markers. |
08 / CYCLE PROTOCOL
Administration Schedule
PULSED CYCLE (PREFERRED)
5mg/day × 10 days — 3–4×/year
CONTINUOUS CYCLE
1–2mg/day × 12 weeks, then 4–8 weeks off. Lower dose, sustained gene signaling. Best for ongoing OA management and general connective tissue maintenance.
RESULTS TIMELINE
Epigenetic changes require sustained exposure — meaningful cartilage regeneration takes 8–16 weeks. Subjective improvement (reduced joint pain, better mobility) often reported at 4–6 weeks. Objective biomarker changes at 12+ weeks.
REQUIRES
Reconstitution with BAC water · Apex V3 Pen · Refrigeration post-reconstitution
⚠ Research reference only. Cartalax is not FDA-approved for human therapeutic use. Research conducted primarily in Russia; published in peer-reviewed gerontology literature. Consult a qualified medical provider before use.